secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K
Filed at:   2024-04-25T23:59:59+00:00
Accession:  0001193125-24-111613
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA earns $9M milestone on FDA approval of Day One's OJEMDA for pediatric low-grade glioma
--------------------------------------------------------------------------------

- XOMA earned $9M milestone from FDA accelerated approval of Day One's OJEMDA (tovorafenib) for relapsed/refractory BRAF-altered pLGG.
- XOMA is entitled to a mid-single digit royalty on global OJEMDA sales; it is the first FDA-approved type II RAF inhibitor for this indication.
- XOMA acquired rights in March 2021 from Viracta for $13.5M upfront, including $54M in potential milestones and royalties.
- CEO Owen Hughes called the milestone a watershed event for children with BRAF-altered low-grade glioma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312524111613/0001193125-24-111613-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312524111613/d815676d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-111613

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer